SCHEMBL463343

SCHEMBL463343

N#Cc1ccc2ncn(C3CC3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 6/20 0.50
KCNH2 Q12809 4/20 0.50
CYP11B1 P15538 9/20 0.44
CYP11B2 P19099 9/20 0.44
HRH3 Q9Y5N1 1/20 0.43
JAK2 O60674 1/20 0.41
JAK3 P52333 1/20 0.41
AKT1 P31749 1/20 0.41
PRKCI P41743 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22862484 0.89 GAA (0.47) IDO1KCNH2CYP11B1CYP11B2HRH3
SCHEMBL5453967 0.81 GABRP (0.51) IDO1KCNH2CYP11B2JAK2AKT1
SCHEMBL17675678 0.80 JAK2 (0.45) IDO1KCNH2CYP11B2JAK2JAK3
SCHEMBL22862841 0.79 IDO1 (0.45) IDO1KCNH2CYP11B1CYP11B2JAK2
SCHEMBL22862483 0.76 IDO1 (0.42) IDO1KCNH2
SCHEMBL15205985 0.76 CYP11B2 (0.41) IDO1KCNH2CYP11B2JAK3AKT1
SCHEMBL15205984 0.76 CYP11B2 (0.41) IDO1KCNH2CYP11B2JAK3AKT1
SCHEMBL17673642 0.76 HSD17B10 (0.42) PRKCI
SCHEMBL4743122 0.76 DRD2 (0.44) CYP11B2PRKCI
SCHEMBL29190582 0.76 DDB1 (0.58) PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 US disclosed
EP-3562306-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2025-02-26 EP disclosed
US-11919883-B2 Metalloenzyme inhibitor compounds JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) 2024-03-05 US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 EP disclosed
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY 2022-12-08 US disclosed
EP-3976009-A2 BAX INHIBITORS AND USES THEREOF Case Western Reserve University (US) 2022-04-06 EP disclosed
US-20220009907-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2022-01-13 US disclosed
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2019-01-10 US disclosed
US-10085984-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-10-02 US disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 WO disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
WO-2018125799-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 WO disclosed
EP-2595482-A1 ALDOSTERONE SYNTHASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-29 EP disclosed
WO-2012012478-A1 ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 IDO1 935/4885KCNH2 2557/4885CYP11B1 2/4885
US-20220009907-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885
US-20180186773-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 IDO1 678/4885KCNH2 1323/4885CYP11B1 481/4885
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF BAX, TMBIM6, BCL2 IDO1 4683/4885KCNH2 4555/4885CYP11B1 715/4885
US-10085984-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885
US-11919883-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH IDO1 1842/4885KCNH2 3417/4885CYP11B1 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.